Bevacizumab (anti-VEGF)

製品コードA2006 別名: rhuMab VEGF

製品コード：A2006 純度：99%

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（48）

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 6.14 mg/ml 内毒素：＜1EU/mg

VEGFR阻害剤の選択性比較

生物活性

製品説明

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

同型

Human IgG1

Targets

VEGFR2

VEGF-A

VEGF

In Vitro
In Vitro	Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.
細胞実験	Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

In Vivo
In Vivo	The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.
動物試験	Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model Dosages: 2 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

参考
https://pubmed.ncbi.nlm.nih.gov/35189151/ https://pubmed.ncbi.nlm.nih.gov/34940991/

参考

https://pubmed.ncbi.nlm.nih.gov/35189151/
https://pubmed.ncbi.nlm.nih.gov/34940991/

製品説明

CAS No.	216974-75-3
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

よくある質問（FAQ）

質問：1：
How to store the antibody?

回答：
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.